Bionano Genomics announces publication on clinical utility of OGM

Bionano Laboratories announced a publication from The University of Texas MD Anderson Cancer Center describing the largest study to-date to evaluate the clinical utility of OGM as an additional tool in the standard cytogenetic workup of hematologic malignancies. Study Overview: Cohort: 519 bone marrow and/or peripheral blood samples collected prospectively in a single institution and analyzed retrospectively. Hematological malignancy subtypes evaluated: T-lymphoblast leukemia, mixed phenotype acute leukemia, B-lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, multiple myeloma, mantle cell lymphoma, myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndrome. Evaluation of OGM’s additional clinical value: The value of OGM was assessed by comparing OGM findings to those of SCGW in two key aspects: analytical sensitivity-defined as all additional somatic aberrations and copy number variants detected exclusively by OGM; and clinical utility-defined as Tier 1 SVs/CNVs detected solely by OGM, which have diagnostic, prognostic, or therapeutic significance. Findings: OGM can enhance analytical sensitivity over that of SCGW. In 58% or 303 of 519 cases, OGM revealed somatic aberrations that were not detected by the SCGW, including Tier 1, Tier 2 and Tier 3 SVs and CNVs. OGM can enhance the clinical utility of SCGW. OGM identified additional Tier 1 variants in 15% or 75 of 519 cases, with detection rates varying by disease type, ranging from 52% in T-ALL to 0% in MPN. Every Tier 1 SV or CNV detected by OGM had direct diagnostic, prognostic, or therapeutic significance, meaning that the detection provided additional clinical utility.